Evidence map›Paper›PMID 35420931›Full record

ArticleScience (New York, N.Y.)2022

Complex regulation of fatty liver disease.

Henry N Ginsberg, Arya Mani

Abstract readComment
In one paragraph

Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Henry N GinsbergDepartment of Medicine, Irving Institute for Clinical and Translational Research, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Arya ManiDepartment of Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, USA.

Funding

The Identification and characterization of genetic variants underlying cardiovascular diseasesR35HL135767 · NHLBI · YALE UNIVERSITY · PI MANI, ARYA · 2017 to 2023
$7.0M
Phenotyping Genetic Disorders of Hepatic Lipid and Lipoprotein Metabolism in Cells, Mice, and MenR35HL135833 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2017 to 2023
$6.7M
The characterization of Cela2a, a novel disease gene for metabolic syndrome in health and diseasesR01DK134329 · NIDDK · YALE UNIVERSITY · PI Arya Mani · 2023 to 2026
$2.6M
The transcriptional regulation of smooth muscle genes by PRDM6 in vascular health and diseasesR01HL171054 · NHLBI · YALE UNIVERSITY · PI Arya Mani · 2024 to 2026
$2.5M
NHLBI NIH HHS R01 HL171054NHLBI NIH HHS R35 HL135767NHLBI NIH HHS R35 HL135833NIDDK NIH HHS R01 DK134329
6 · The paper itself

Abstract

Hepatic lipogenesis is fine-tuned by mechanistic target of rapamycin (mTOR) signaling.

Indexed as

LipogenesisLiverMechanistic Target of Rapamycin Complex 1Non-alcoholic Fatty Liver DiseaseHumansSignal TransductionMechanistic Target of Rapamycin Complex 1

Identifiers

PMID35420931
PMCPMC9619413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.